reports
Bavarian Nordic aktionærer påmindes om udløbet af tilbudsperioden vedr...
Bavarian Nordic aktionærer påmindes om udløbet af tilbudsperioden vedrørende overtagelsestilbuddet fra konsortium bestående af Nordic Capital og Permira MÅ IKKE UDGIVES, OFFENTLIGGØRES ELLER DISTRIBUERES, DIREKTE ELLER INDIREKTE, I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF DE RELEVANTE LOVE ELLER FORORDNINGER I DEN PÅGÆLDENDE JURISDIKTION København, Danmark, 13. oktober 2025 – Der henvises til selskabsmeddelelsen af 26. august 2025 (nr. 24/2025) og selskabsmeddelelsen af 29. september 2025 (nr. 27/2025) vedrørende det kontante frivillige og af bestyrelsen anb...
Bavarian Nordic shareholders are reminded of expiry of the offer perio...
Bavarian Nordic shareholders are reminded of expiry of the offer period regarding the takeover offer from consortium consisting of Nordic Capital and Permira NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, 13 October 2025 – Reference is made to the company announcement dated 26 August 2025 (no. 24/2025) and the company announcement dated 29 September 2025 (no. 27/2025) regarding the all-cash voluntary board-recommended pu...
Konsortium bestående af Nordic Capital og Permira modtager den sidste ...
Konsortium bestående af Nordic Capital og Permira modtager den sidste regulatoriske godkendelse i forhold til overtagelsestilbuddet til aktionærerne i Bavarian Nordic MÅ IKKE UDGIVES, OFFENTLIGGØRES ELLER DISTRIBUERES, DIREKTE ELLER INDIREKTE, I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF DE RELEVANTE LOVE ELLER FORORDNINGER I DEN PÅGÆLDENDE JURISDIKTION København, Danmark, 9. oktober 2025 – Med henvisning til selskabsmeddelelserne af 26. august 2025 (nr. 24/2025 og 25/2025) og selskabsmeddelelsen af 29. september 2025 (nr. 27/2025) vedrørende det kontante friv...
Consortium consisting of Nordic Capital and Permira receives final reg...
Consortium consisting of Nordic Capital and Permira receives final regulatory approval in respect of its takeover offer to the shareholders of Bavarian Nordic NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, 9 October, 2025 – With reference to the announcements of 26 August 2025 (no. 24/2025 and no. 25/2025) and the announcement of 29 September 2025 (no. 27/2025) concerning the all-cash voluntary recommended public takeover...
Emergent BioSolutions to Report Third Quarter 2025 Financial Results o...
Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025 GAITHERSBURG, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, October 29, 2025, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2025. Participants can access the conference call live via and also by visiting the page of Emergent’s website. To participate via telephone, please register in advance at this . Upon registration, all telephone participants will receive a confirmation email detailing ...
Bavarian Nordic rapporterer positive toplinjeresultater for mpox-/kopp...
Bavarian Nordic rapporterer positive toplinjeresultater for mpox-/koppevaccine i børn Det primære endemål blev opnået i det kliniske forsøg, som viste sammenlignelige sikkerhedsdata og immunresponser for MVA-BN mellem børn i alderen 2-11 år og voksne.Resultaterne vil understøtte en ansøgning om udvidelse af indikationen hos EMA i 2026. KØBENHAVN, Danmark, 7. oktober 2025 – Bavarian Nordic A/S (OMX: BAVA) rapporterede i dag toplinjeresultater fra et klinisk forsøg med selskabets MVA-BN® mpox-/koppevaccine i børn i alderen 2 til 11 år. Forsøget () inkluderede 460 personer fordelt pi to grup...
Bavarian Nordic Reports Positive Topline Data for Mpox/Smallpox Vaccin...
Bavarian Nordic Reports Positive Topline Data for Mpox/Smallpox Vaccine in Pediatric Population Primary endpoint was met in clinical study, demonstrating a comparable safety profile and a non-inferior immune response for MVA-BN in children aged 2-11 years compared to adults.Results will support filing for label extension with EMA in 2026. COPENHAGEN, Denmark, October 7, 2025 – Bavarian Nordic A/S (OMX: BAVA) today reported topline results from a clinical study of its MVA-BN® mpox/smallpox vaccine in children 2 to 11 years of age. The study () enrolled 460 individuals in two cohorts: child...
Konsortium bestående af Nordic Capital og Permira forlænger tilbudsper...
Konsortium bestående af Nordic Capital og Permira forlænger tilbudsperioden til 14. oktober 2025 og giver en opdatering vedrørende de regulatoriske godkendelser i forhold til overtagelsestilbuddet til aktionærerne i Bavarian Nordic MÅ IKKE UDGIVES, OFFENTLIGGØRES ELLER DISTRIBUERES, DIREKTE ELLER INDIREKTE, I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF DE RELEVANTE LOVE ELLER FORORDNINGER I DEN PÅGÆLDENDE JURISDIKTION København, Danmark, 29. september 2025 – Med henvisning til selskabsmeddelelsen af 26. august 2025 (nr. 24/2025) angående offentliggørelsen af ti...
Consortium consisting of Nordic Capital and Permira extends offer peri...
Consortium consisting of Nordic Capital and Permira extends offer period until 14 October 2025 and provides update on regulatory approvals in respect of the takeover offer to the shareholders of Bavarian Nordic NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, September 29, 2025 – With reference to the announcement of 26 August 2025 (no. 24/2025) regarding the publication of the offer document (the "Offer Document") concerni...
Emergent BioSolutions Recognizes Several Important Observances to Help...
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone GAITHERSBURG, Md., Sept. 24, 2025 (GLOBE NEWSWIRE) -- In recognition of several observances in September meant to keep the national opioid poisoning epidemic front and center, Emergent BioSolutions Inc. (NYSE: EBS) today recommitted to its leadership combating the opioid crisis through a multi-faceted approach focused on awareness, education and widespread access to naloxone, including NARCAN® Nasal Spray 4 mg and KLOXXADO® (naloxone...
Emergent BioSolutions Secures $29 Million in MCM Product Orders from I...
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner GAITHERSBURG, Md., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured new purchase orders from an international government partner for a multi-product supply agreement valued at $29 million (USD). The orders span several product offerings within Emergent’s medical countermeasures (MCM) business, including countermeasures for smallpox, anthrax and botulism threats, and reflects the increasing priority governments are placing on defense ...
Emergent BioSolutions Secures $17 Million Contract Modification for Or...
Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply TEMBEXA® (brincidofovir) oral suspension...
Emergent BioSolutions Receives New Contract Modification for ACAM2000®...
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to the U.S. government. Deliveries are expected to begin this month. This brings the total projected sales for ACAM2000® vaccine and ancil...
Kapitalforhøjelse i Bavarian Nordic A/S som følge af medarbejderes udn...
Kapitalforhøjelse i Bavarian Nordic A/S som følge af medarbejderes udnyttelse af tegningsoptioner KØBENHAVN, Danmark, 5. september 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har forhøjet sin aktiekapital med nominelt DKK 3.818.710 som følge af medarbejderes udnyttelse af tegningsoptioner. Kapitalforhøjelsen er sket uden fortegningsret for selskabets eksisterende aktionærer eller andre. Aktierne er tegnet kontant til følgende tegningskurser pr. aktie á nominelt DKK 10: 363.156 stk. aktier til DKK 206,82 og 18.715 stk. aktier til DKK 190,11. Det samlede provenu til ...
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warran...
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise COPENHAGEN, Denmark, September 5, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 3,818,710 as a consequence of employees’ exercise of warrants. The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. The shares were subscribed for in cash at the following prices per share of nominally DKK 10: 363,156 shares at DKK 206.82 and 18,715 shares at DKK 190.11. The total procee...
Emergent BioSolutions Awarded $30 Million Contract Modification for CY...
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS® (Anthrax Vaccine Adsorbed...
Emergent BioSolutions Underscores Continued Support of Increasing Nalo...
Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day Pro Football Hall of Famer and Ready to Rescue campaign spokesperson, Emmitt Smith, and Release Recovery Founder/CEO, Zac Clark, plan to visit several U.S. college campuses to educate on opioid emergency preparednessNew sponsorship of Mobilize Recovery's “Campus Surge” initiative brings addiction prevention and recovery support to higher education institutions GAITHERSBURG, Md., Aug. 29, 2025 (GLOBE NEWSWIRE) -- In honor of Inter...
Emergent BioSolutions to Participate in Upcoming Investor Conferences
Emergent BioSolutions to Participate in Upcoming Investor Conferences GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: Wells Fargo 20th Annual Healthcare ConferenceSeptember 4, 20253:00 pm ETWebcast link One-on-one meetings HCW 27th Annual Global Investment ConferenceSeptember 9, 20251:30 PM ETWebcast link One-on-one meetings Please contact your conference representative to request one-on-one meetings. Participa...
Offentliggørelse af redegørelse af bestyrelsen vedrørende overtagelses...
Offentliggørelse af redegørelse af bestyrelsen vedrørende overtagelsestilbud til aktionærerne i Bavarian Nordic fra konsortium ledet af Nordic Capital og Permira MÅ IKKE UDGIVES, OFFENTLIGGØRES ELLER DISTRIBUERES, DIREKTE ELLER INDIREKTE, I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF DE RELEVANTE LOVE ELLER FORORDNINGER I DEN PÅGÆLDENDE JURISDIKTION København, Danmark, August 26, 2025 – Med henvisning til selskabsmeddelelsen af 26. august 2025 (nr. 24/2025) angående offentliggørelsen af tilbudsdokumentet vedrørende det frivillige offentlige overtagelsestilbud ...
Publication of statement by the Board of Directors in respect of the t...
Publication of statement by the Board of Directors in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, August 26, 2025 – With reference to Bavarian Nordic A/S' ("Bavarian Nordic" or the "Company") announcement of 26 August 2025 (no. 24/2025) regarding the publication of the offer document concerning th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.